Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

58 trials

NCT06479616
Recruiting
A Long-term Follow-up Study in Participants Who Received CS-101
Not applicable · China · 1 site
Registry update: 26 Oct 2026
NCT06655662
Recruiting
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Phase 1 · China · 3 sites
Registry update: 23 Oct 2024
NCT06302491
Recruiting
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Phase 2 · China · 5 sites
Registry update: 27 Feb 2026
NCT06313398
Recruiting
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Early phase 1 · United States · 1 site
Registry update: 28 Sept 2026
NCT06490627
Recruiting
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Phase 2 · Pakistan · 1 site
Registry update: 30 May 2025
NCT06280378
Recruiting
β-Thalassemia Treatment With KL003 Cell Injection
Phase 1/2 · China · 2 sites
Registry update: 2 Nov 2026
NCT06073860
Recruiting
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Not applicable · South Korea · 2 sites
Registry update: 6 Nov 2024
NCT06271512
Recruiting
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Not applicable · United States · 6 sites
Registry update: 11 Feb 2025
NCT06465550
Recruiting
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Phase 1 · China · 3 sites
Registry update: 24 Jun 2024
NCT05693909
Recruiting
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Phase 2 · Denmark, Greece, Italy, Poland · 28 sites
Registry update: 24 Sept 2025
NCT05991336
Recruiting
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Not applicable · China · 1 site
Registry update: 4 Nov 2026
NCT05757245
Recruiting
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
Phase 1 · China · 1 site
Registry update: 18 Apr 2023
NCT05762510
Recruiting
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
Early phase 1 · China · 1 site
Registry update: 9 May 2023
NCT05736419
Recruiting
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Phase 2 · United States · 6 sites
Registry update: 3 Jun 2026
NCT06314529
Recruiting
Long-term Follow-up Study of BHC001 for TDT
Not applicable · China · 2 sites
Registry update: 18 Mar 2024
NCT05851105
Recruiting
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
Early phase 1 · China · 1 site
Registry update: 29 Nov 2024
NCT05799118
Recruiting
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Not applicable · Angola, Argentina, Belgium, Brunei, Cyprus, Denmark, Spain, Greece, Israel, Italy, Malaysia, Nigeria, Pakistan, Portugal, United States · 26 sites
Registry update: 20 Mar 2024
NCT05508932
Recruiting
Atrial Fibrillation in Beta-Thalassemia
Not applicable · Italy · 1 site
Registry update: 24 Feb 2026
NCT05477563
Recruiting
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Phase 3 · Germany, Italy, Saudi Arabia, United States · 6 sites
Registry update: 23 Mar 2026
NCT06250595
Recruiting
European Rare Blood Disorders Platform (ENROL)
Not applicable · Spain · 1 site
Registry update: 9 Feb 2024

Ordered by registry start date. Freshness and sponsorship never change the order.